Literature DB >> 11399674

Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery.

K E Wiley1, A P Davenport.   

Abstract

The ability of four endogenous vasodilators, nitric oxide (NO; 0.01 - 30 microM), atrial (ANP), brain (BNP) and C-type (CNP) natriuretic peptide (0.1 - 300 nM), to reverse endothelin-1 (ET-1; 10 nM) constrictions in human resistance and conductance coronary arteries (CA) in vitro was investigated. ET-1 (0.1 - 300 nM) constricted resistance CA more potently than conductance CA (P<0.05; EC(50) values 2.98 nM (95% CI: 1.49 - 5.95 nM and 8.58 (4.72 - 15.6 nM) respectively)). The NO-donor diethylamine NONOate fully reversed the ET-1 constriction in conductance CA (E(MAX) 127+/-9.16%), however only partial reversal was observed in resistance CA (E(MAX) 78.8+/-8.13; P<0.05). The soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (100 microM) reduced the maximum response to diethylamine NONOate to 76.9+/-14.4% in conductance CA (P<0.05), but had no effect on resistance CA (E(MAX) 77.2+/-18.4%). There was no difference between responses to ANP in conductance and resistance CA (EC(50) values 4.25 nM (0.84 - 21.4 nM) and 18.4 nM (2.92 - 116 nM), E(MAX) 53.1+/-14.7% and 48.6+/-11.8% respectively). BNP was a more potent vasodilator of conductance than resistance CA. In conductance CA the mean EC(50) value was 2.4 nM (0.74 - 7.75 nM), E(MAX) 54.5+/-14.9%. Concentration-response curves to BNP were incomplete in resistance CA. Concentration-response curves to CNP were incomplete in both conductance and resistance CA. The greater potency of ET-1 in resistance vessels may exacerbate the effects of increased circulating levels of the peptide in disease. Only NO could fully reverse ET-1 mediated constrictions in conductance CA, and none of the dilators tested could completely counteract constrictions in resistance CA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399674      PMCID: PMC1572818          DOI: 10.1038/sj.bjp.0704119

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Inducible nitric oxide synthase expression in coronary arteries of transplanted human hearts with accelerated graft arteriosclerosis.

Authors:  A Lafond-Walker; C L Chen; S Augustine; T C Wu; R H Hruban; C J Lowenstein
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

2.  Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin.

Authors:  F D Russell; J N Skepper; A P Davenport
Journal:  J Cardiovasc Pharmacol       Date:  1998-03       Impact factor: 3.105

3.  Myocardial circulatory and metabolic effects of atrial natriuretic peptide after coronary artery bypass grafting.

Authors:  F Valsson; S Lundin; K Kirnö; T Hedner; Y Saito; S E Ricksten
Journal:  Anesth Analg       Date:  1996-11       Impact factor: 5.108

4.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

5.  C-type natriuretic peptide in chronic renal failure and its action in humans.

Authors:  T Igaki; H Itoh; S Suga; N Hama; Y Ogawa; Y Komatsu; M Mukoyama; A Sugawara; T Yoshimasa; I Tanaka; K Nakao
Journal:  Kidney Int Suppl       Date:  1996-06       Impact factor: 10.545

6.  Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  J Pharmacol Exp Ther       Date:  1997-02       Impact factor: 4.030

7.  Calcium-activated potassium channels and nitrate-induced vasodilation in human coronary arteries.

Authors:  R Bychkov; M Gollasch; T Steinke; C Ried; F C Luft; H Haller
Journal:  J Pharmacol Exp Ther       Date:  1998-04       Impact factor: 4.030

8.  Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta.

Authors:  C R Bacon; N R Cary; A P Davenport
Journal:  Circ Res       Date:  1996-10       Impact factor: 17.367

9.  Response of human artery, vein, and cultured smooth muscle cells to atrial and C-type natriuretic peptides.

Authors:  L M Zhang; M R Castresana; M H McDonald; J H Johnson; W H Newman
Journal:  Crit Care Med       Date:  1996-02       Impact factor: 7.598

10.  Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans.

Authors:  W G Haynes; C J Ferro; K P O'Kane; D Somerville; C C Lomax; D J Webb
Journal:  Circulation       Date:  1996-05-15       Impact factor: 29.690

View more
  14 in total

Review 1.  Natriuretic peptide C receptor signalling in the heart and vasculature.

Authors:  Robert A Rose; Wayne R Giles
Journal:  J Physiol       Date:  2007-11-15       Impact factor: 5.182

2.  Exercise limits the production of endothelin in the coronary vasculature.

Authors:  Vincent J de Beer; Shawn B Bender; Yannick J Taverne; Fen Gao; Dirk J Duncker; M Harold Laughlin; Daphne Merkus
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-11       Impact factor: 4.733

3.  Characterization of the snake venom ligand [125I]-DNP binding to natriuretic peptide receptor-A in human artery and potent DNP mediated vasodilatation.

Authors:  G Singh; J J Maguire; R E Kuc; J N Skepper; M Fidock; A P Davenport
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

4.  Constriction of rat extra-splenic veins to lipopolysaccharide involves endothelin-1.

Authors:  Arnaud Mansart; Lewis J Ruff; Mark P Ariaans; Jonathan J Ross; Charles S Reilly; Nicola J Brown; Susan Kaufman; Zoë L S Brookes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-16       Impact factor: 3.000

5.  Effect of nitric oxide donors and noradrenaline on Ca2+ release sites and global intracellular Ca2+ in myocytes from guinea-pig small mesenteric arteries.

Authors:  Vladimír Pucovský; Dmitri V Gordienko; Thomas B Bolton
Journal:  J Physiol       Date:  2002-02-15       Impact factor: 5.182

6.  Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

7.  Pharmacological regulation of outflow resistance distal to Schlemm's canal.

Authors:  Fiona McDonnell; W Michael Dismuke; Darryl R Overby; W Daniel Stamer
Journal:  Am J Physiol Cell Physiol       Date:  2018-04-06       Impact factor: 4.249

Review 8.  C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target.

Authors:  Natalie G Lumsden; Rayomand S Khambata; Adrian J Hobbs
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 9.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors.

Authors:  L León-Mateos; J Mosquera; L Antón Aparicio
Journal:  Redox Biol       Date:  2015-09-10       Impact factor: 11.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.